Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Common Equity (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Common Equity for 15 consecutive years, with $45.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 45.28% to $45.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.4 million through Dec 2025, down 45.28% year-over-year, with the annual reading at $45.4 million for FY2025, 45.28% down from the prior year.
  • Common Equity hit $45.4 million in Q4 2025 for Cardiff Oncology, down from $48.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $140.4 million in Q4 2021 to a low of $45.4 million in Q4 2025.
  • Historically, Common Equity has averaged $90.4 million across 5 years, with a median of $84.8 million in 2023.
  • Biggest five-year swings in Common Equity: surged 1932.52% in 2021 and later tumbled 45.28% in 2025.
  • Year by year, Common Equity stood at $140.4 million in 2021, then decreased by 24.27% to $106.3 million in 2022, then tumbled by 34.42% to $69.7 million in 2023, then grew by 18.94% to $82.9 million in 2024, then crashed by 45.28% to $45.4 million in 2025.
  • Business Quant data shows Common Equity for CRDF at $45.4 million in Q4 2025, $48.8 million in Q3 2025, and $58.6 million in Q2 2025.